Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D | Starlite/ChEMBL | No references |
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0704 | 0.0704 |
Trypanosoma cruzi | hexokinase, putative | 0.0508 | 1 | 0.5 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.0704 | 0.0704 |
Brugia malayi | Hexokinase family protein | 0.0157 | 0.2797 | 0.2797 |
Loa Loa (eye worm) | hypothetical protein | 0.0346 | 0.6684 | 0.6684 |
Loa Loa (eye worm) | hexokinase | 0.0319 | 0.6113 | 0.6113 |
Echinococcus multilocularis | hexokinase type 2 | 0.0508 | 1 | 1 |
Onchocerca volvulus | 0.0319 | 0.6113 | 0.6113 | |
Trypanosoma cruzi | hexokinase, putative | 0.0508 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0508 | 1 | 1 |
Onchocerca volvulus | 0.0508 | 1 | 1 | |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0704 | 0.0704 |
Brugia malayi | Hexokinase family protein | 0.0508 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0161 | 0.2885 | 0.2885 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0039 | 0.0375 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0182 | 0.3317 | 0.3317 |
Leishmania major | hexokinase, putative | 0.0508 | 1 | 0.5 |
Brugia malayi | hexokinase type II | 0.0161 | 0.2885 | 0.2885 |
Trypanosoma brucei | hexokinase | 0.0508 | 1 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0039 | 0.0375 | 0.5 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.0704 | 0.0704 |
Brugia malayi | hypothetical protein | 0.0182 | 0.3317 | 0.3317 |
Echinococcus granulosus | hexokinase | 0.0508 | 1 | 1 |
Toxoplasma gondii | hexokinase | 0.0508 | 1 | 0.5 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0042 | 0.0432 | 0.0432 |
Schistosoma mansoni | hexokinase | 0.0508 | 1 | 1 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0055 | 0.0704 | 0.0704 |
Onchocerca volvulus | 0.0508 | 1 | 1 | |
Plasmodium vivax | hexokinase, putative | 0.0508 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0508 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0508 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0508 | 1 | 1 |
Loa Loa (eye worm) | hexokinase | 0.0508 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0055 | 0.0704 | 0.0704 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0704 | 0.0704 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0704 | 0.0704 |
Loa Loa (eye worm) | hypothetical protein | 0.0036 | 0.0318 | 0.0318 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0042 | 0.0432 | 0.0432 |
Brugia malayi | Hexokinase family protein | 0.0319 | 0.6113 | 0.6113 |
Onchocerca volvulus | Hexokinase homolog | 0.0319 | 0.6113 | 0.6113 |
Echinococcus multilocularis | hexokinase | 0.0508 | 1 | 1 |
Onchocerca volvulus | 0.0508 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.0508 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0508 | 1 | 1 |
Trypanosoma brucei | hexokinase, putative | 0.0508 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 1 | 0.0508 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0508 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0508 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0161 | 0.2885 | 0.2885 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0042 | 0.0432 | 0.0432 |
Loa Loa (eye worm) | hexokinase | 0.0508 | 1 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0508 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0046 | 0.0512 | 0.0512 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0042 | 0.0432 | 0.0432 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.0704 | 0.0704 |
Treponema pallidum | hexokinase (hxk) | 0.0508 | 1 | 0.5 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0046 | 0.0512 | 0.0512 |
Plasmodium falciparum | hexokinase | 0.0508 | 1 | 0.5 |
Onchocerca volvulus | 0.0182 | 0.3317 | 0.3317 | |
Loa Loa (eye worm) | hexokinase | 0.0157 | 0.2797 | 0.2797 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | > 99 uM | PUBCHEM_BIOASSAY: Dose response confirmation uHTS hits for MazEF TA System activators via a fluorescence-based single-stranded RNase assay counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504720, AID504743] | ChEMBL. | No reference |
EC50 (functional) | > 99 uM | PUBCHEM_BIOASSAY: Dose response confirmation uHTS hits for MazEF TA System activators via a fluorescence-based single-stranded RNase assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504720, AID504743] | ChEMBL. | No reference |
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.8184 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Vif-A3F Interactions: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.